Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.56 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960526 | 1.00 | NOD1 (0.56) | NOD1PLA2G2CPLA2G10KMT2AFAAH | |
| SCHEMBL1958048 | 1.00 | NOD1 (0.56) | NOD1PLA2G2CPLA2G10KMT2AFAAH | |
| SCHEMBL29669622 | 1.00 | NOD1 (0.56) | NOD1PLA2G2CPLA2G10KMT2AFAAH | |
| SCHEMBL29669584 | 1.00 | NOD1 (0.56) | NOD1PLA2G2CPLA2G10KMT2AFAAH | |
| SCHEMBL1960769 | 1.00 | NOD1 (0.56) | NOD1PLA2G2CPLA2G10KMT2AFAAH | |
| SCHEMBL15387262 | 1.00 | NOD1 (0.56) | NOD1PLA2G2CPLA2G10KMT2AFAAH | |
| SCHEMBL1959616 | 1.00 | NOD1 (0.56) | NOD1PLA2G2CPLA2G10KMT2AFAAH | |
| SCHEMBL32889378 | 1.00 | NOD1 (0.56) | NOD1PLA2G2CPLA2G10KMT2AFAAH | |
| SCHEMBL16538865 | 0.93 | NOD1 (0.49) | NOD1PLA2G2CPLA2G10KMT2AFAAH | |
| SCHEMBL15706317 | 0.91 | NOD1 (0.51) | NOD1PLA2G2CPLA2G10KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441760-B2 | Amino diacids containing peptide modifiers | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-10-14 | — | — | US | disclosed |
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240002433-A1 | AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2024-01-04 | — | — | US | disclosed |
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11634455-B2 | Amino diacids containing peptide modifiers | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2023-04-25 | — | — | US | disclosed |
| US-20230101323-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| CN-110003055-B | Amino diacids containing peptide modifiers | 佩特雷化学和生物制药学实验室有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-9856292-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856292-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3218392-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160137696-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-19 | — | — | US | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160137696-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | NOD1 3890/4885PLA2G2C 1260/4885PLA2G10 1382/4885 |
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | NOD1 447/4885PLA2G2C 1000/4885PLA2G10 657/4885 |
| US-12441760-B2 | Amino diacids containing peptide modifiers | PTMS, PEPD, NGLY1 | NOD1 2038/4885PLA2G2C 241/4885PLA2G10 1717/4885 |
| US-20160137696-A1 | Immunomodulators | CD74, ICOS, HAVCR2 | NOD1 447/4885PLA2G2C 1000/4885PLA2G10 657/4885 |
| US-20230101323-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | NOD1 447/4885PLA2G2C 1000/4885PLA2G10 657/4885 |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | NOD1 3734/4885PLA2G2C 843/4885PLA2G10 1301/4885 |
| US-11634455-B2 | Amino diacids containing peptide modifiers | PTMS, PEPD, VIP | NOD1 2108/4885PLA2G2C 222/4885PLA2G10 1617/4885 |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | NOD1 3734/4885PLA2G2C 843/4885PLA2G10 1301/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | NOD1 447/4885PLA2G2C 1000/4885PLA2G10 657/4885 |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | NOD1 3620/4885PLA2G2C 927/4885PLA2G10 1352/4885 |
| US-20240002433-A1 | AMINO DIACIDS CONTAINING PEPTIDE MODIFIERS | PTMS, PEPD, NGLY1 | NOD1 2038/4885PLA2G2C 241/4885PLA2G10 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.